Additionally, it has been previously shown that M2 CD163+ macrophages heavily express CD30, suggesting that the effects of brentuximab vedotin may be at least partially explained by architectural modifications in the tumor microenvironment, hence the anecdotal reports of the ADC’s activity in CD30- lymphoma [88]. The gene discussed is TNFRSF8; the disease is neoplasm.